


The burden of antimicrobial resistance (AMR) in Fiji

Executive summary

- Antimicrobial Resistance (AMR) is a major global health threat, over **100 lives** have been lost each year since 1990 in Fiji due to AMR.
- In 2021, there were an estimated **127 UI (90-165)** deaths attributable to AMR and **491 UI (344-638)** deaths associated with AMR in this location.
- The largest number of deaths associated with AMR in 2021 occurred among those aged **50 to 69** in the country.
- Among the most deadly pathogen-drug combinations in 2021 were *Staphylococcus aureus* resistant to methicillin, *Klebsiella pneumoniae* resistant to carbapenems and *Acinetobacter baumannii* resistant to carbapenems.

Figure 1 Number of deaths by underlying cause, and those associated with AMR in 2021




- In 2021, the number of deaths associated with AMR (orange bar in *figure 2*) were high compared to the most relevant underlying causes of death (depicted in blue) in the country. AMR associated deaths occur within multiple Global Burden of Disease (GBD) causes of death and AMR is not an underlying cause of death by itself.
- At the [2024 United Nations General Assembly high level meeting on antimicrobial resistance](#), country members agreed to aim for a **10% reduction** compared to 2019 baseline (**from 4.95 to 4.45 million**) in the global number of deaths associated with AMR by 2030. But [our forecast](#) indicates that in absence of concerted action, deaths associated with AMR could reach **5.5 million** (UI 4.8 - 6.2) if current trends continue. For Fiji, a 10% reduction means to decrease the number of deaths associated with AMR to **460**, but currently the trend for this country could reach up to **537 UI [377-722]** AMR-associated deaths in 2030.

AMR in Fiji

Key takeaways

- Antimicrobial Resistance (AMR) is a major global health threat, over *a million lives* have been lost each year since 1990.
- Globally, 4.71 (95% Uncertainty Interval (UI) 4.2-5.2) million deaths were associated with bacterial drug-resistant infections in 2021.
- And 1.14 (UI 1 - 1.3) million deaths were attributable to bacterial drug-resistant infection in the same year.
- *39 (UI 33 - 46) million deaths* directly attributable to bacterial AMR are projected to occur between 2025-2050 unless concerted action is taken. This equates to three deaths every minute.

Figure 2 Comparing 30 years of infection related deaths, and those associated with and attributable to AMR in Fiji between 1990 and 2019.



- To look at these and more visualization interactively visit [Measuring Infectious Causes and Resistance Outcomes for Burden Estimation \(MICROBE\)](#)
- In **Fiji** in 2021, there were an estimated **127 UI (90-165)** deaths attributable to AMR and **491 UI (344-638)** deaths associated with AMR. Here “*attributable deaths*” are considered to be those that would have been prevented had the drug-resistant bacteria causing the infections not been drug-resistant. “*Associated deaths*” are considered to be those that would not have occurred had the infections been prevented entirely.
- Across 204 countries, **Fiji has the 78th highest** age-standardized mortality rate associated with AMR in 2021.
- *Table 1* shows the bacteria which caused most deaths in 2021 (↑ indicates an increasing estimated annual rate between 1990-2021, ↓ indicates a decreasing annual trend), and *table 2* shows the pathogen-drug combinations which caused most deaths in 2021.

Table 1. Bacteria which cause most deaths in 2021 (Number of deaths in parenthesis)

	Overall susceptible and resistant	Associated	Attributable
Burden rank	Staphylococcus aureus 115 UI (87-144) ↑	Escherichia coli 75 UI (50-101) ↑	Acinetobacter baumannii 25 UI (20-31) ↑
	Klebsiella pneumoniae 112 UI (84-140) ↑	Klebsiella pneumoniae 71 UI (50-91) ↑	Klebsiella pneumoniae 21 UI (15-27) ↑
	Pseudomonas aeruginosa 94 UI (70-117) ↑	Acinetobacter baumannii 62 UI (46-78) ↑	Escherichia coli 16 UI (10-22) ↑
	Escherichia coli 90 UI (67-112) ↑	Staphylococcus aureus 62 UI (42-91) ↑	Staphylococcus aureus 16 UI (10-21) ↑
	Streptococcus pneumoniae 89 UI (68-110) ↓	Pseudomonas aeruginosa 57 UI (39-74) ↑	Pseudomonas aeruginosa 14 UI (9-20) ↑
	Acinetobacter baumannii 65 UI (48-82) ↑	Streptococcus pneumoniae 56 UI (36-77) ↓	Streptococcus pneumoniae 14 UI (8-19) ↓
	Mycobacterium tuberculosis 48 UI (35-61) ↓	Enterobacter spp. 18 UI (14-23) ↑	Enterobacter spp. 6 UI (4-7) ↑
	Group A Streptococcus 23 UI (16-30) ↑	Enterococcus faecalis 14 UI (10-17) ↑	Enterococcus faecium 4 UI (3-5) ↑
	Enterobacter spp. 22 UI (16-28) ↑	Enterococcus faecium 13 UI (10-17) ↑	Serratia spp. 3 UI (2-4) ↑
	Enterococcus faecalis 22 UI (16-28) ↑	Proteus spp. 13 UI (9-17) ↑	Enterococcus faecalis 2 UI (1-3) ↑

Annualized rate of change (1990-2021): <-3% (blue), -1.5% to 0% (light blue), 0% to 1.5% (pink), 1.5% to 3% (red), 3% to 5% (dark red), >5.0% (black)


Table 2. Combinations which cause most deaths in 2021 (Number of deaths in parenthesis)

	Associated	Attributable
Burden Rank	Escherichia coli Aminopenicillin 70 UI (38-102) ↑	Acinetobacter baumannii Carbapenems 16 UI (11-20) ↑
	Acinetobacter baumannii Carbapenems 62 UI (46-78) ↑	Staphylococcus aureus Methicillin 11 UI (7-15) ↑
	Acinetobacter baumannii 4GC 60 UI (44-76) ↑	Klebsiella pneumoniae Carbapenems 10 UI (7-12) ↑
	Klebsiella pneumoniae Aminoglycosides 58 UI (41-76) ↑	Streptococcus pneumoniae Carbapenems 8 UI (5-12) ↓
	Acinetobacter baumannii Fluoroquinolones 57 UI (42-72) ↑	Acinetobacter baumannii Fluoroquinolones 8 UI (6-9) ↑
	Acinetobacter baumannii Beta-Lactam/Lactamase Inhib. 51 UI (38-65) ↑	Escherichia coli 3GC 8 UI (5-10) ↑
	Acinetobacter baumannii 3GC 51 UI (36-66) ↑	Pseudomonas aeruginosa Carbapenems 7 UI (4-10) ↑
	Escherichia coli 3GC 51 UI (31-71) ↑	Klebsiella pneumoniae Aminoglycosides 6 UI (4-8) ↑
	Klebsiella pneumoniae 3GC 48 UI (34-63) ↑	Pseudomonas aeruginosa Fluoroquinolones 4 UI (3-6) ↑
	Acinetobacter baumannii Anti-pseudomonal 48 UI (34-61) ↑	Klebsiella pneumoniae 3GC 3 UI (2-4) ↑

Annualized rate of change (1990-2021): <-3% (blue), -3% to -1.5% (light blue), -1.5% to 0% (light blue), 0% to 1.5% (pink), 1.5% to 3% (red), 3% to 5% (dark red), >5.0% (black)

- Independently of antimicrobial resistance, the infectious syndromes accounting for the most deaths in 2021 were as follows (estimated thousands of deaths in parenthesis) bloodstream infections (451 UI (336-565)), lower respiratory infection (excl. COVID) (380 UI (292-469)), diarrhea (134 UI (70-197)), infections of the skin and subcutaneous systems (83 UI (52-114)) and urinary tract infections and pyelonephritis (58 UI (40-75)).

Figure 3. Number of deaths associated with AMR by age group between 1990-2020 and 2050 projection



- In Fiji, people aged 50 to 69 saw the largest number of deaths associated with AMR both in 1990 and 2021, which indicates that 50 to 69 continues to be particularly vulnerable to infections which are resistant to antibiotics. In 2021, the number of deaths associated with AMR among the 50 to 69 was 194 UI (126-261), whereas the mortality rate per 100,000 was 561 UI (415-706).

Data sources for Fiji

In total, 520 million individual records or isolates covering 19,513 study-location-years were used as input data to our estimation process. The subset of input data for this country is shown below.

Table 3. Data inputs for Fiji by source type

Source type	Years	Sample size	Sample size units
Microbial or laboratory data without outcome	2010-2021	650	Isolates
Microbial or laboratory data with outcome	2010-2021	1,808	Isolates
Literature studies	1990-2021	843	Cases/isolates/susceptibility tests

More information

About GRAM:

The purpose of the Global Research on AntiMicrobial resistance (GRAM) project is to **generate accurate and timely estimates of the magnitude and trends in antimicrobial resistance (AMR) burden** across the world, which can be used to inform treatment guidelines and agendas for decision-making and research, detect emerging problems and monitor trends to inform global strategies, as well as facilitate the assessment of interventions over time.

GRAM is the flagship project of the University of Oxford–IHME Strategic Partnership. GRAM was launched with support from the United Kingdom Department of Health and Social Care’s Fleming Fund, and the Wellcome Trust.

All resources:

For all resources on AMR analysis at IHME, visit <https://www.healthdata.org/antimicrobial-resistance>.

To look at these and more visualization interactively visit [Measuring Infectious Causes and Resistance Outcomes for Burden Estimation \(MICROBE\)](#).

Data sources:

To download the list of data input sources by country, and AMR results by region, visit the [Global Health Data Exchange \(GHDx\)](#).

Contact us:

- For inquiries about the analysis and questions from government officials, health departments, or research institutions: engage@healthdata.org
- For media-related inquiries: media@healthdata.org
- **Bluesky:** @ihmeuw.bsky.social
- **Twitter:** @IHME_UW
- **Facebook:** <https://www.facebook.com/IHMEUW>
- **LinkedIn:** <https://www.linkedin.com/company/institute-for-health-metrics-and-evaluation>